YD Bio Limited Ordinary Shares
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $281.9M
- Price
- $3.98
- % Change (Daily % change from the live per-ticker quote feed.)
- +18.10%
- Volume
- 87.8K
About
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Quick stats
Shares outstanding70.8M
Computed float1.4M
Float / shares2.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002011674
Websitehttps://www.ydesgroup.com
AI Summary
AI-generated1/9
minorbullishproduct launch
YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
YD Bio launched two chrono-nutrition products in Taiwan—a daytime lipid-soluble “Golden Triangle” formula and a nighttime zinc-plus-calcium formula—marking the first step in its physician-partnership ecosystem initiative.
The products were co-developed with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute, utilizing a bottoms-up model where practicing clinicians define formulation needs based on patient observations.
Management intends to repeat this capital-light model with other physician partners to generate recurring consumer revenue and build relationships that support future engagement with the company's core diagnostics and clinical services.
Red flags
- Consumer health products face intense competition and depend on market acceptance
- Scientific manuscript referenced is under review and not yet peer-reviewed